Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NI[4fYMzNjVvMUWgcm0> NF\PO|k4OiCq NIHrbYxqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MXeyOVc6ODlyNx?=
U2932  MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXuyMlUuOTVibl2= NVfCc5V6PzJiaB?= MXXpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MY[yOVc6ODlyNx?=
OCI-LY7 NHjVR3ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWnFV5FvOi53LUG1JI5O M{f5O|czKGh? MnntbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NETjfmQzPTd7MEmwOy=>
Farage NHvJV2RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnX5Nk42NTF3IH7N MomwO|IhcA>? NGC3W3NqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NH;le3YzPTd7MEmwOy=>
LY7/EBV MmDyR4VtdCCYaXHibYxqfHliQYPzZZk> MXKyMlUuOTVibl2= MXq3NkBp NV\xcol1cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NVe1SGFHOjV5OUC5NFc>
U2932/EBV NHv5NYFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYi0eXl7Oi53LUG1JI5O MlrhO|IhcA>? Mn7PbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NF3NO44zPTd7MEmwOy=>
HCT116 M3rJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPDS|I2NTVyMECgcm0> MkfsNlQhcA>? NGPMPJVFVVOR MUjpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NVXkO2k1OjV2OUK1NVU>
ACH-2 NGHBfmpHfW6ldHnvckBCe3OjeR?= MV6xMVkhdk1? NHv2O2UzPCCq M4i5OYlv\HWlZYOgTGlXNTFiRX72JIV5eHKnc4Ppc44> NFHiWYszPTF2OUS2Oy=>
MCF-10A NG\OU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X3TGlEPTB;MD6xO:KyOC5yMTDuUS=> MWCyOFk2PDh3Nh?=
MCF-7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMUFCtVAvOjBibl2= NUTOe4xtOjR7NUS4OVY>
SK-BR-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7Yb|ZKSzVyPUGuNFDDuTBwM{Wgcm0> NEnJZlUzPDl3NEi1Oi=>
MDA-MB-231 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHlTWM2OD1yLk[4xtExNjF2IH7N MWqyOFk2PDh3Nh?=
PC3 NHHvNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jCemlEPTB;MT62OeKyOC5|NTDuUS=> M1rxW|I1QTV2OEW2
HCT116 MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvUOYNKSzVyPUGuNFDDuTBwMECgcm0> MVWyOFk2PDh3Nh?=
HCT116-p21-/- MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPHcWVKSzVyPUGuNlbDuTBwM{egcm0> MWSyOFk2PDh3Nh?=
S1 NG\FSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTdwNkhCtVAvOjlibl2= NHrXOY0zPDl3NEi1Oi=>
SW620 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rOUWlEPTB;MD65N:KyOC5{OTDuUS=> MlXSNlQ6PTR6NU[=
LOX-IMVI NUPiUoJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrHTlFbUUN3ME2wMlg4yrFyLkCzJI5O MlrtNlQ6PTR6NU[=
UACC-62 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;XTWM2OD1yLkW2xtExNjF4IH7N MXuyOFk2PDh3Nh?=
MDA-MB-435 NFrTfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjpTWM2OD1yLkmwxtExNjB4IH7N MYiyOFk2PDh3Nh?=
SF-295 MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnp[pBKSzVyPUCuPFjDuTBwMUWgcm0> MVuyOFk2PDh3Nh?=
A549 NUfR[FlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwMkdCtVAvOjRibl2= M4fSclI1QTV2OEW2
H460 MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYe5OpNoUUN3ME2yMlU5yrFyLkiwJI5O NV3tbYRDOjR7NUS4OVY>
EKVX NXy2cpBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nDPWlEPTB;MT6zN:KyOC5|NDDuUS=> MVeyOFk2PDh3Nh?=
H146 MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMkNCtVAvODdibl2= Mm\TNlQ6PTR6NU[=
H526 M4rXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT0WnRKSzVyPUCuNVXDuTBwMEOgcm0> NXfmb3pVOjR7NUS4OVY>
HuT-78 M3jzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFwN{RCtVAvPDRibl2= NV64[2pqOjR7NUS4OVY>
HA M1vhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;aZmkxNjZ{NT2xNI5O NGfnbXY1QCCq NX7aNlBycW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? NIj1W5AzPDd5MUWxNC=>
MS-275 NH36OoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3FVGM{OC54MkWtNVBvVQ>? MnLVOFghcA>? Ml3mbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> MoLpNlQ4PzF3MUC=
CD4 T NFrzboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:0PEBp MmH2SWM2OD12LkZCtVEvOCCwTR?= MVGyOFczOjR3NB?=
CD4 T NUjp[I1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\BZmo1QCCq MX\DR|UxRTFyN9MxNVI3KG6P Ml;PNlQ4OjJ2NUS=
CD4+ T NInmPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHFR|UxRTNibl2= NFv6OI0zPDR7NUGwOS=>
A549 MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTiNVDjiJNzMEFCpI5O NYTGfmxpOjRxM{[vOFghcA>? MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MY[yOFQ5PTd7OR?=
JJN3 NWTyN5NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTPNlQwPDhiaB?= NGrBWXJGSzVyPEJihKlvVTtiNElihKlp MV:yOFA{ODF3MB?=
OPM-2 MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLKNlQwPDhiaB?= NV;FOpZjTUN3MIO9NgKBkW6POzC0PQKBkWh? NXTTcG8zOjRyM{CxOVA>
RPMI-8226 NED3NW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqyOE81QCCq MoraSWM2OHN;MT645qCKdk19IES45qCKcA>? MWCyOFA{ODF3MB?=
U266 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;MNlQwPDhiaB?= M{O2fWVEPTC|PUGw5qCKdk19IES45qCKcA>? MVmyOFA{ODF3MB?=
CA46 MUjBdI9xfG:|aYOgRZN{[Xl? NGLZbWg3KGh? NVflRVFkcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= MoG1NlM6PjZzNkS=
DG75 NWDQWol7SXCxcITvd4l{KEG|c3H5 M1[3TFYhcA>? NV7kTXVScW6mdXPld{BvdyCjcH;weI9{cXN? NXnneo9lOjN7Nk[xOlQ>
Ramos MkfMRZBweHSxc3nzJGF{e2G7 NYW5SXU{PiCq MXLpcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO= M1jGRlI{QTZ4MU[0
ST486 MlnVRZBweHSxc3nzJGF{e2G7 NWPxU5VQPiCq NWXBVIN5cW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ NF7y[|QzOzl4NkG2OC=>
HuT78 MVnBdI9xfG:|aYOgRZN{[Xl? MlzGNU8yOC9zMECgcm0> NHjOdVk1QCCq NYTNS2NwcW6mdXPld{BieG:ydH;zbZMh[XRiMTDuUS=> NIToZZYzOzV|MkezNi=>
DpVp35 NUHWWmtJSXCxcITvd4l{KEG|c3H5 NW\L[5hoOS9zMD:xNFAhdk1? MUW0PEBp NVW3SZpvcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NVjvTJNuOjN3M{K3N|I>
DpVp50 NX3sXlN4SXCxcITvd4l{KEG|c3H5 NEjwPWQyNzFyL{GwNEBvVQ>? M{Hvb|Q5KGh? NYjSWpVpcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= M2nr[VI{PTN{N{Oy
DpP75  NYjkeY5[SXCxcITvd4l{KEG|c3H5 NHT3TWoyNzFyL{GwNEBvVQ>? MUO0PEBp MoD5bY5lfWOnczDicJVvfCCjcH;weI9{cXN? MWmyN|U{Ojd|Mh?=
SKOV-3 NHzReHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH21SFcy6oDVMkDuUS=> NUP0bIFrPzJiaB?= MYXEUXNQ MoDtdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> M4nacFI{ODFyM{S4
Brca1 WT Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HPNVHjiJN{MH7N NGe3eJo4OiCq NVTiXIZnTE2VTx?= M1X5bJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv M{PsVFI{ODFyM{S4
Brca1 Null Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjLNgKBmzJybl2= M3uzdVczKGh? NGLORXVFVVOR NFfo[pRz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? M4riR|I{ODFyM{S4
OVCAR-8  MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHzNgKBmzJybl2= MmjZO|IhcA>? M1XBe2ROW09? M4nmUZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MnK4NlMxOTB|NEi=
NCI/ADR-RES NVPObFQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnFNgKBmzJybl2= NGL2eVE4OiCq MkHaSG1UVw>? NHHjOo1z\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NX;qR5VIOjNyMUCzOFg>
HCT116 NILXTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXxN|Y2KG6PLUWwJO69VQ>? NXy3WphYOjRiaB?= NXmwXpd4TE2VTx?= MmLlbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> M4\4[VIzQTJ2OUW4
RKO NVuxV5FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XYSFUhdk1vNUCg{txO MorSNlQhcA>? MoD0SG1UVw>? MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NVHhT4lkOjJ7MkS5OVg>
CO115 NFnrZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXO1JI5ONTVyIN88US=> NX3id3RSOjRiaB?= MmnlSG1UVw>? NGjlZnlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? M2m3flIzQTJ2OUW4
HFS NY\Ze2xPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknQOUBvVQ>? NInLOnEzPC92OD:3NkBp NY\USmRLcW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? NVnGOnFLOjJzME[yPFI>
LNCaP NVfGdVN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KwOVUhdk1? NVzSRnFGOjRxNEivO|IhcA>? M3nne4lvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> MUmyNlExPjJ6Mh?=
A549 NWrTfmpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYq1JI5O MWGyOE81QC95MjDo NWfTb|VJcW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? M2Xab|IzOTB4Mkiy
697  NXHafWtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVKwWnZOUUN3MPMAjV3jiIl{LkZCpI5O M1TOfVIyPTN6MkG2
697-R MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXDN2ZoUUN3MPMAjV3jiIl6LkdCpI5OyqB? NEPQWWwzOTV|OEKxOi=>
HUT78 NXricXNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF22NllKSzVyPUGgcm0> NVTubYRJOjFzOUi1OFU>
THJ-16T MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLKNlcyKG6P M1PDOlI1KGh? M2DjOYlvcGmkaYTzJINmdGxiZ4Lve5Rp NIHMcJEzODhzMEW2PC=>
HCT116 MXvGeY5kfGmxbjDBd5NigQ>? M1TxV|IxKG6P MYK4JIg> NH70T2Jud2S3bHH0[ZMhfHKjboPjdolxfCCuZY\lcJMh\m:{IHj1coRz\WS|IH;mJIdmdmW|IHnuJIVqfGincjDkbZJm[3Srb36= M{fwTlIxPzN7NEW0
B104  MYTGeY5kfGmxbjDBd5NigQ>? NHzHZnYzKG6P NH22UIkzPC92OD:3NkBp NHfjfpBqdmO{ZXHz[ZMhfGinIIP1doZi[2ViZYjwdoV{e2mxbjDv[kBETDJywrC= MXiyNFY5PjVyNR?=
HL-60  NXnTUlRNS3m2b4TvfIlkcXS7IFHzd4F6 NFn2OFIyNTVyMDDuUS=> MYqyOEBp NWrZ[2xwcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= M{LHVVIxPjJ2MU[z
HP100 Mlf2R5l1d3SxeHnjbZR6KEG|c3H5 MnHaNU02ODBibl2= MW[yOEBp NH\JPGRqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NX3kfFVmOjB4MkSxOlM>
HL-60  Mm[zSpVv[3Srb36gRZN{[Xl? NUH4SYZ[OTBibl2= NXnoOVY5PC94L{G2JIg> Mk\rbY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq NGDQdVQzODZ{NEG2Ny=>
HP100 Mk[1SpVv[3Srb36gRZN{[Xl? MXmxNEBvVQ>? NXi1b3lPPC94L{G2JIg> MmDlbY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq NUnJUZptOjB4MkSxOlM>
HL-60  M4nGd2Z2dmO2aX;uJGF{e2G7 MUKxNE02ODBibl2= M2XYWlQhcA>? MYDk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? MUmyNFYzPDF4Mx?=
HP100 MorJSpVv[3Srb36gRZN{[Xl? MmT0NVAuPTByIH7N M{XmUlQhcA>? NFXtVoxl\WO{ZXHz[ZMhfGinIHjpd5RwdmViZHXhZ4V1gWyjc3WgLGhFSUNrIHHjeIl3cXS7wrC= MmTLNlA3OjRzNkO=
11z M{nvTGtqdmG|ZTDBd5NigQ>? NWrZSJExOy1zMECgcm0> NXL2U5dVemWmdXPld{BJTEGFIHXufplu[XSrYzDhZ5Rqfmm2eTCoTWM2OMLiPTC2MlUhyrFiMD62JI5ud2xxTDm= M3jmOlIxPjB3MUS0
SKOV-3 NIfPfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWW0M|gwOTZibl2= Mny1OFghcA>? M4\TWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NVzadXNnOjB2MES1OlQ>
OVCAR-3 NWDTSI9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYexR4pLPC96L{G2JI5O MmLEOFghcA>? Ml\3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NX\ycZExOjB2MES1OlQ>
HBL-2 NGW4VGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DRXFIuOTBibl2= M1jVRlI1KGh? MVjJR|UxRTRwMzDuUS=> NGP3Z3czODB4OEC4NC=>
Jeko-1 Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXyyMVUxKG6P NYLZU3VJOjRiaB?= NWGyN|NZUUN3ME2xNUBvVQ>? NFq1UpgzODB4OEC4NC=>
Granta-519 NGrpVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\w[FUuPDBibl2= MmXrNlQhcA>? MWTJR|UxRTV6LkWgcm0> MV6yNFA3QDB6MB?=
L1236 M4TwN2N6fG:2b4jpZ4l1gSCDc4PhfS=> Ml3tNUBvVS1zMECg{txO MUe0PEBp MlHxSWM2OD1yLkC3JO69VQ>? M3fqPVE6OjN|NEew
L428 NYfvSmhoS3m2b4TvfIlkcXS7IFHzd4F6 MlzhNUBvVS1zMECg{txO MYS0PEBp NWfzS4ZXTUN3ME2wMlQ{KM7:TR?= M1vuS|E6OjN|NEew
KM-H2 MkDzR5l1d3SxeHnjbZR6KEG|c3H5 NIn6N4gyKG6PLUGwNEDPxE1? NEK4Nmc1QCCq NImyZWFGSzVyPUCuOVgh|ryP M3;JelE6OjN|NEew
L540Cy MoLqR5l1d3SxeHnjbZR6KEG|c3H5 NW\GTGVpOSCwTT2xNFAh|ryP M{jESFQ5KGh? NInGWGtGSzVyPUCuNVYh|ryP NEHwTXoyQTJ|M{S3NC=>
G401 MXfGeY5kfGmxbjDBd5NigQ>? MVexNEBvVQ>? M4G2WVI1NzR6L{eyJIg> M3fBZ2ROW09? MXLpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= NEC5e|MyQTJ{MUW4Oi=>
STM91-01 MnXMSpVv[3Srb36gRZN{[Xl? NX7XOm1kOTBibl2= M4DnVFI1NzR6L{eyJIg> NXqzdGIyTE2VTx?= Mn7ubY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u NHnmZm8yQTJ{MUW4Oi=>
SJSC  MkXVSpVv[3Srb36gRZN{[Xl? M17FN|ExKG6P NVzpb|JWOjRxNEivO|IhcA>? M3;u[2ROW09? MV\pcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= NUTkbplsOTl{MkG1PFY>
BT16  MmGxSpVv[3Srb36gRZN{[Xl? MlXUNVAhdk1? MWCyOE81QC95MjDo M2PLbWROW09? NHzYSJFqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NHvSV|kyQTJ{MUW4Oi=>
NCI-H1299 NGrnOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rOUWlEPTB;ND62xtExNjJibnevcYw> NUeyeppWOTlzN{m4PVA>
NCI-2882 NITX[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG4dWVKSzVyPUGuOuKyOC5yNDDu[{9udA>? M4C1W|E6OTd7OEmw
HCC95 M{DyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz1TWM2OD1{LkZCtVAvODVibnevcYw> MUixPVE4QTh7MB?=
NCI-H23 M1rVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\WTWM2OD1{LkpCtVAvOiCwZz;tcC=> M17OfVE6OTd7OEmw
NCI-H157 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFwNtMxNE4xOiCwZz;tcC=> NI\mOJQyQTF5OUi5NC=>
NCI-H460 Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJwMdMxNE4xPyCwZz;tcC=> M2OyRlE6OTd7OEmw
NCI-H1975 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7FSo5xUUN3ME2xMlPDuTBwMESgcocwdWx? NEHFTokyQTF5OUi5NC=>
NCI-H820 M2HtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwNNMxNE4yKG6pL33s MU[xPVE4QTh7MB?=
NCI-H1650 NF;jPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrWTWM2OD12LkpCtVAvOyCwZz;tcC=> M1m3XVE6OTd7OEmw
DTC1 M2\NVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwNUGgcm0> NXPEVVJWOTh3Nk[yOFY>
KAO NH;iTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES1b4hKSzVyPUCuPVEhdk1? MWixPFU3PjJ2Nh?=
SU-CCS-1 M4\mc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwOEmgcm0> NH3OXJYyQDV4NkK0Oi=>
SYO-1 NHLV[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG4fZNKSzVyPUCuOlchdk1? M172fVE5PTZ4MkS2
FUJI M1nSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXQTWM2OD1zLkOxJI5O NGi3OFIyQDV4NkK0Oi=>
SKNMC NVXZNIV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXmTWM2OD1zLkG3JI5O NYKxWVNSOTh3Nk[yOFY>
402-91 NGLyZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPyOWlKSzVyPUGuNlYhdk1? MnryNVg2PjZ{NE[=
1765-92 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHGyd4pKSzVyPUGuO|chdk1? NUHYN2c4OTh3Nk[yOFY>
JN-DSRCT-1 NGezeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;RNWxKSzVyPUGuNlUhdk1? MoHWNVg2PjZ{NE[=
NMS-2PC NUnvdGVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP2TWM2OD1yLkixJI5O MXKxPFU3PjJ2Nh?=
HL60 M32xUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPlbJhKSzVyPUGuPFYhdk1? NFPZfG0yQDV4NkK0Oi=>
A549 M{LreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInKXIlKSzVyPUOuNlQhdk1? MU[xPFU3PjJ2Nh?=
SW480 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPZdmV4UUN3ME2yMlY6KG6P NETROngyQDV4NkK0Oi=>
MCF7 NF7aTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnkTWM2OD1|LkW1JI5O NXOzTIlDOTh3Nk[yOFY>
PC-3 NXzjWY5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLKTWM2OD1{LkWxJI5O NXz5d4FSOTh3Nk[yOFY>
MMRU NX;KVJVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\o[G5KSzVyPUKuOVchdk1? M2HxUVE5PTZ4MkS2
Hs68 NES1TZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TlRmlEPTB;PkGwJI5O NXnFNGI5OTh3Nk[yOFY>
hMSC-001F NWHreos3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLaVmRKSzVyPU6xNEBvVQ>? MYKxPFU3PjJ2Nh?=

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 18 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID